To include your compound in the COVID-19 Resource Center, submit it here.
Alnylam began a single-blind, placebo-controlled, dose-escalation, U.K. Phase I/II
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury